Brief: Monte Rosa Therapeutics Q3 Pretax Profit USD -23.788 Million
07/11/2024 12:00
Nov 07 (Reuters) - Monte Rosa Therapeutics Q3 net income USD -23.859 million. * Q3 operating expenses USD 35.743 million * Q3 operating income USD -26.527 million
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million